今日药学

2022, v.32(05) 383-386

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

PD-1/PD-L1抑制剂联合PC化疗方案对EGFR野生型晚期肺腺癌患者疾病控制率及生存质量的影响
Effects of PD-1/PD-L1 Inhibitor Combined with PC Chemotherapy on Disease Control Rate and Quality of Life in Patients with Wild-type Advanced Lung Adenocarcinoma with EGFR

刘自威;
LIU Ziwei;The Fifth People's Hospital of Puyang City;

摘要(Abstract):

目的 探讨PD-1/PD-L1(程序性死亡分子1/程序性死亡-配体1)抑制剂+PC(培美曲塞+顺铂)化疗方案对EGFR(表皮生长因子受体)野生型晚期肺腺癌患者疾病控制率及生存质量的影响。方法 选取2018年8月~2021年1月某院收治的104例晚期肺腺癌(EGFR野生型)患者,按照随机数字表法分为观察组(n=52)和对照组(n=52),其中对照组给予PC化疗,观察组给予PD-1/PD-L1抑制剂+PC化疗,治疗3个疗程后对比两组疾病控制率、肿瘤标志物[CA199(糖类抗原199)、CA125、CA153及CEA(癌胚抗原)]水平、免疫功能[CD4+(T淋巴细胞)、CD3+(T淋巴细胞)、CD3+、CD4+、CD4+/CD8+/CD8+]及EORTC-QLQ-C30(癌症患者生存质量评定量表)评分。结果 观察组疾病控制率(90.38%,47/52)高于对照组(73.08%,38/52,P<0.05);治疗后观察组血清CA199、CA125、CA153及CEA水平低于对照组(P<0.05);治疗后观察组CD4+]及EORTC-QLQ-C30(癌症患者生存质量评定量表)评分。结果 观察组疾病控制率(90.38%,47/52)高于对照组(73.08%,38/52,P<0.05);治疗后观察组血清CA199、CA125、CA153及CEA水平低于对照组(P<0.05);治疗后观察组CD4+、CD3+、CD3+、CD4+、CD4+/CD8+/CD8+水平高于对照组(P<0.05);治疗后观察组EORTC-QLQ-C30评分高于对照组(P<0.05)。结论 PD-1/PD-L1抑制剂+PC化疗方案应用于EGFR野生型晚期肺腺癌患者,可有效提高疾病控制率,改善患者免疫功能,提高生存质量。
OBJECTIVE To investigate the effects of programmed death molecule 1/programmed death-ligand 1(PD-1/PD-L1)inhibitor combined with pemetrexed+cisplatin(PC) chemotherapy on disease control rate and quality of life in patients with epidermal growth factor receptor(EGFR) wild-type advanced lung adenocarcinoma.METHODS A total of 104 patients with advanced lung adenocarcinoma(EGFR wild-type) admitted to our hospital from August 2018 to January 2021 were selected and divided into observation group(n=52) and control group(n=52) according to random number table method.The control group was given PC chemotherapy,and the observation group was given PD-1/PD-L1 inhibitor and PC chemotherapy.Tne disease control rate,tumor markers [CA199(carbohydrate antigen 199),CA125,CA153 and CEA],immune function [CD4+水平高于对照组(P<0.05);治疗后观察组EORTC-QLQ-C30评分高于对照组(P<0.05)。结论 PD-1/PD-L1抑制剂+PC化疗方案应用于EGFR野生型晚期肺腺癌患者,可有效提高疾病控制率,改善患者免疫功能,提高生存质量。
OBJECTIVE To investigate the effects of programmed death molecule 1/programmed death-ligand 1(PD-1/PD-L1)inhibitor combined with pemetrexed+cisplatin(PC) chemotherapy on disease control rate and quality of life in patients with epidermal growth factor receptor(EGFR) wild-type advanced lung adenocarcinoma.METHODS A total of 104 patients with advanced lung adenocarcinoma(EGFR wild-type) admitted to our hospital from August 2018 to January 2021 were selected and divided into observation group(n=52) and control group(n=52) according to random number table method.The control group was given PC chemotherapy,and the observation group was given PD-1/PD-L1 inhibitor and PC chemotherapy.Tne disease control rate,tumor markers [CA199(carbohydrate antigen 199),CA125,CA153 and CEA],immune function [CD4+(T lymphocyte),CD3+(T lymphocyte),CD3+,CD4+,CD4+/CD8+/CD8+] and EORTC-QLQ-C30(quality of life assessment scale for cancer patients) were compared between the two groups after 3 courses of treatment.RESULTS The disease control rate of observation group(90.38%,47/52) was significantly higher than that of control group(73.08%,38/52)(P<0.05).After 3 courses of treatment,the levels of serum CA199,CA125,CA153 and CEA in the observation group were lower than those in the control group(P<0.05).The levels of CD4+] and EORTC-QLQ-C30(quality of life assessment scale for cancer patients) were compared between the two groups after 3 courses of treatment.RESULTS The disease control rate of observation group(90.38%,47/52) was significantly higher than that of control group(73.08%,38/52)(P<0.05).After 3 courses of treatment,the levels of serum CA199,CA125,CA153 and CEA in the observation group were lower than those in the control group(P<0.05).The levels of CD4+,CD3+,CD3+and CD4+and CD4+/CD8+/CD8+in the observation group were higher than those in the control group(P<0.05).After treatment,the EORTC-QLQ-C30 score in the observation group was higher than that in the control group(P<0.05).CONCLUSION PD-1/PD-L1 inhibitor combined with PC chemotherapy regimen can effectively improve disease control rate,immune function and the quality of life in patients with EGFR wild-type advanced lung adenocarcinoma.

关键词(KeyWords): PD-1/PD-L1抑制剂;PC化疗方案;EGFR野生型晚期肺腺癌;疾病控制率
PD-1/PD-L1 inhibitor;PC chemotherapy regimen;EGFR wild-type advanced lung adenocarcinoma;disease control rate

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 刘自威;
LIU Ziwei;The Fifth People's Hospital of Puyang City;

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享